Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation

American Journal of Transplantation

Volumn 4, Issue 11, 2004, Pages 1845-1851

  Borrows, Richard ^a   Loucaidou, Marina ^a   Van Tromp, Jen ^a   Cairns, Tom ^a   Griffith, Megan ^a   Hakim, Nadey ^a   McLean, Adam ^a   Palmer, Andrew ^a   Papalois, Vassilios ^a   Taube, David ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Complications; Corticosteroids; Rejection; Renal; Transplant

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; CIDOFOVIR; DACLIZUMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ANTIBODY PRODUCTION; ARTICLE; AVASCULAR NECROSIS; BLOOD VESSEL; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRADUCTAL CARCINOMA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; STEROID THERAPY; URINARY TRACT INFECTION; WEIGHT GAIN;

CONTINENTAL POPULATION GROUPS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETHNIC GROUPS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; RECURRENCE; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS;

EID: 7244261982     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00583.x     Document Type: Article

References (35)

1. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72(6 Suppl): S5-8.
2. Matas A, Humar A, Gillingham K et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62: 704-714.
3. Starzl TE, Marchioro TL, Rifkind D, Holmes JH, Rowlands DT Jr, Waddell WR. Factors in successful renal transplantation. Surgery 1964; 56: 296-318.
4. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72(12 Suppl): S75-80.
5. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-1446.
6. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
7. Fernandez-Fresnedo G, Palomar R, Escallada R et al. Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. Nephrol Dial Transplant 2001; 16(Suppl I): 105-109.
8. Roodnat JI, Mulder PG, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704-1710.
9. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
10. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348(9028): 643-8.
11. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657.
12. Ahsan N, Hricik D, Matas A et al. Prednisolone withdrawal in kidney transplant recipients on cyclosporine and Mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
13. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose Tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234-241.
14. Dunn TB, Asolati M, Holman DM et al. Long-term outcome of a prospective trial of steroid withdrawal after kidney transplantation. Surgery 1999; 125: 155-159.
15. Cole E, Landsberg D, Russell D et al. A Pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845-850.
16. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66: 1207-1210.
17. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
18. Pirsch J, Miller J, Deierhoi M, Vincenti F, Filo RS. A comparison of Tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
19. Boots JM, Christiaans MH, van Duijnhoven EM, van Suylen R-J, van Hooff JP. Early steroid withdrawal in renal transplantation with Tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709.
20. Grewal HP, Thistlewaite JR Jr, Loss GE et al. Corticosteroid cessation 1 week following renal transplantation using Tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998; 30: 1378-1379.
21. Kaufman DB, Leventhal R, Koffron AJ et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: Tacrolimus/ mycophenolate mofetil versus Tacrolimus/sirolimus. Transplantation 2002; 73: 169-177.
22. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended Daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331-1339.
23. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
24. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
26. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of Tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
27. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-1067.
28. Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-1203.
29. Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69: 2357-2360.
30. Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11: 565-573.
31. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
32. Meier-Kriesche H-U, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.
33. Madden RL, Mulhern JG, Benedetto BJ et al. Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transpl Int 2000; 13: 344-350.
34. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75: SS3-SS24.
35. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(Suppl 15): S1-86.